Prolifagen
Prolifagen is a startup headquartered in Doylestown, United States, founded in 2025. It has raised at least $3.0m in outside funding, according to its filings with the US Securities and Exchange Commission (Form D), which puts it at the seed stage.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Funding
Prolifagen has raised at least $3.0m in outside funding, according to its Form D filings with the US Securities and Exchange Commission. Form D figures are a minimum: not every round is filed.
R&D ecosystem
Prolifagen sits inside the Philadelphia region R&D ecosystem in the Global R&D Labs Directory.
Other startups in Doylestown
Related
Questions and answers
What does Prolifagen do?
Prolifagen is classed in biotechnology in its filings with the US Securities and Exchange Commission.
How much has Prolifagen raised?
At least $3.0m, according to its Form D filings with the US Securities and Exchange Commission.
Where is Prolifagen based?
Prolifagen is headquartered in Doylestown, United States.
When was Prolifagen founded?
Prolifagen was founded in 2025.
Source record: SEC EDGAR (Form D filings).
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.